Bibliography
- Pettit GR, Singh SB, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45:209-11
- Lin CM, Singh SB, Chu PS, et al. Interactions of tubulin with potent and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988;34:200-8
- Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-20
- Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001;21:93-102
- Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Brit J Cancer 1999;80:57-64
- Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005;115:2992-3006
- Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34
- Woods JA, Hadfield JA, Pettit GR, et al. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Brit J Cancer 1995;71:705-11
- Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989;28:6984-91
- Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34
- Beauregard DA, Thelwall PE, Chaplin DJ, et al. MRI and MRS of combretastin A4 prodrug-induced disruption of tumor perfusion and energetic status. Brit J Cancer 1998;77:1761-7
- Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours. Int J Radiat Oncol Biol Phys 1998;42:895-8
- Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-95
- Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9
- Chaplin DJ, Horsman MR. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother Oncol 1994;30:59-65
- Siemann DW, Chaplin DJ. An update on the clinical development of drugs to disable tumor vasculature. Expert Opin Drug Discov 2007;2:1-11
- Gould S, Westwood FR, Curwen JO, et al. Effect of pretreatment with atenolol and nifedipene on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Institute 2007;99:1724-8
- Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998;42:899-903
- Siemann DW, Mercer E, Lepler SE, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6
- Petit I, Karajannis MA, Vincent L, et al. The microtubule–targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial – dependent cell death. Blood 2008;111:1951-61
- Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54:1491-6
- Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 2003;13:53-61
- Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39
- Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours. Radiother Oncol 2001;60:155-61
- Ahmed B, Landuyt W, Griffioen AW, et al. In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation. Anticancer Res 2006;26:307-10
- Murata R, Overgaard J, Horsman MR. Combining combretastatin A-4 disodium phosphate and radiation in a fractionated schedule to improve local tumour control in mice. Radiother Oncol 2000;56:S98
- Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncologica 2002;41:91-7
- Horsman MR, Murata R, Breidahl T, et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000;476:311-23
- Grosios K, Loadman PM, Swaine DJ, et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229-33
- Wildiers H, Ahmed B, Guetens G, et al. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 2004;40:284-90
- Horsman MR, Murata R, Overgaard J. Combination studies with combretastatin and radiation: effects in early and late responding normal tissues. Radiother Oncol 2002;64:S50
- Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1018-24
- Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 2001;61:4716-22
- Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000;5:11-5
- Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004;60:1233-40
- Siemann DW, Shi W. Dual targeting of tumor vasculature: Combining antiangiogenic (Avastin) and vascular disrupting (CA4P or OXi4503) agent therapy. Anticancer Res 2008;28:2027-32
- Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16
- Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38
- Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22
- Anderson HL, Yap JT, Miller MP, et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30
- Cooney M, Savvides P, Agarwala S, et al. Phase II study of combretastatin A4 phosphate (CA4P) in subjects with advanced anaplastic thyroid carcinoma (ATC) [Abstract 5580]. American Society of Clinical Oncology Annual Meeting; Atlanta, GA, USA; 2 – 6 June, 2006
- Cooney M, Radiovoyevitch T, Dowlati A, et al. Cardiovascular safety profile of Combretastatin A4 Phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100
- Ng Q, Goh V, Carnell D, et al. Phase Ib trial of Combretastatin A4 Phosphate (CA4P) in combination with radiotherapy (RT): Initial clinical results [Abstract 3117]. American Society of Clinical Oncology Annual Meeting; Orlando, FL, USA; 13 – 17 May, 2005
- Bilenker J, Flaherty K, Rosen M, et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005;11:1527-33
- Rustin GJ, Nathan PD, Boxhall J, et al. A Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer [Abstract]. J Clin Oncol 2005;23:3013
- Akerley W, Schabel M, Morrell G, et al. A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies [Abstract 14060]. American Society of Clinical Oncology Annual Meeting; Chicago, IL, USA; 1 – 5 June, 2007
- Rustin G, Jayson G, Reed N, et al. Fosbretabulin (Combretastatin A-4 Phosphate [CA4P]) Carboplatin and Paclitaxel is active in patients with platinum resistant ovarian cancer [Abstract 315]. International Gynecologic Cancer Society Meeting; 2008
- Nathan P, Judson I, Padhani A, et al. A phase I study of the safety, tolerability and antitumor activity of escalating doses of Combretastatin A4 Phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors – final results [Abstract 3504]. American Society of Clinical Oncology Annual Meeting; Chicago, IL, USA; 30 May – 3 June, 2008
- Jones R, Ewer M. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006;6:1249-69